Insulet Co. (NASDAQ:PODD) Receives Average Recommendation of “Moderate Buy” from Analysts

Insulet Co. (NASDAQ:PODD) has received an average rating of “Moderate Buy” from the fifteen brokerages that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $277.13.

A number of analysts recently commented on PODD shares. Morgan Stanley lifted their price target on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. TD Cowen lifted their price target on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. JPMorgan Chase & Co. lifted their price target on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a report on Thursday, December 12th. Canaccord Genuity Group lifted their price target on Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Finally, Sanford C. Bernstein started coverage on Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target on the stock.

Insider Activity at Insulet

In related news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Insulet

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Integrated Wealth Concepts LLC boosted its holdings in shares of Insulet by 1.7% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock worth $596,000 after purchasing an additional 42 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Insulet by 1.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock valued at $1,146,000 after acquiring an additional 43 shares during the last quarter. Glenmede Trust Co. NA lifted its stake in shares of Insulet by 2.3% in the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock valued at $484,000 after acquiring an additional 47 shares during the last quarter. Graypoint LLC lifted its stake in shares of Insulet by 5.3% in the 4th quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock valued at $243,000 after acquiring an additional 47 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB lifted its stake in shares of Insulet by 9.6% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier’s stock valued at $140,000 after acquiring an additional 47 shares during the last quarter.

Insulet Stock Up 1.0 %

Shares of NASDAQ:PODD opened at $287.67 on Friday. The stock has a market cap of $20.18 billion, a price-to-earnings ratio of 49.26, a PEG ratio of 3.49 and a beta of 1.23. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet has a 12-month low of $160.19 and a 12-month high of $288.05. The business’s 50 day moving average is $269.95 and its 200 day moving average is $240.32.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.13. The company had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $518.50 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. During the same quarter in the previous year, the firm earned $0.71 earnings per share. On average, sell-side analysts forecast that Insulet will post 3.22 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.